Deutsche Bank Aktiengesellschaft Forecasts Strong Price Appreciation for Pediatrix Medical Group (NYSE:MD) Stock

Pediatrix Medical Group (NYSE:MD) had its price target raised by Deutsche Bank Aktiengesellschaft from $9.00 to $15.00 in a research report report published on Monday,Benzinga reports. The firm currently has a hold rating on the stock.

A number of other brokerages have also commented on MD. UBS Group raised their price target on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Truist Financial lifted their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday. StockNews.com upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Jefferies Financial Group upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating and upped their target price for the stock from $8.00 to $14.00 in a report on Thursday, September 26th. Finally, Mizuho raised their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Monday. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Pediatrix Medical Group has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Stock Performance

Shares of MD stock opened at $16.03 on Monday. The stock has a 50 day moving average price of $11.99 and a two-hundred day moving average price of $9.59. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.38 and a current ratio of 1.42. The company has a market capitalization of $1.38 billion, a P/E ratio of -5.24, a PEG ratio of 2.35 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.29 earnings per share. Analysts expect that Pediatrix Medical Group will post 1.19 earnings per share for the current year.

Insider Buying and Selling at Pediatrix Medical Group

In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares in the company, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the transaction, the director now owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James D. Swift sold 11,100 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the sale, the chief executive officer now owns 170,001 shares of the company’s stock, valued at $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,538 shares of company stock worth $373,664. 1.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

Large investors have recently added to or reduced their stakes in the company. Quest Partners LLC boosted its stake in Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after buying an additional 622 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Pediatrix Medical Group by 3.5% during the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock valued at $245,000 after purchasing an additional 1,088 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Pediatrix Medical Group by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock worth $170,000 after buying an additional 1,167 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after buying an additional 1,524 shares during the last quarter. Finally, SummerHaven Investment Management LLC raised its position in shares of Pediatrix Medical Group by 3.8% during the 2nd quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company’s stock valued at $422,000 after buying an additional 2,069 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.